Our commitments | Takeda 2025 Annual Integrated Report
Our commitments
"We have a clear vision at Takeda: to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. We pursue our vision with a strong foundation in our values of Integrity, Fairness, Honesty and Perseverance, with Integrity at the core.”
Patients
Putting patients first
We work to remove the many complex barriers to access and equity that may prevent people from getting the treatments they need.
One of the most significant barriers is affordability. With government spending under pressure, patients may be left to bear the cost of health care themselves. We’re working to bridge this affordability gap, offering different forms of pricing for our medicines and special patient assistance programs for people unable to afford treatment.
We have principles governing access to our medicines and vaccines; these principles are built into our business from R&D to commercialization. Our Access Principles ensure we take a local approach, responding to local patient needs and addressing the barriers unique to each health care system.
Improving long-term community health in the U.S.
An estimated 1 in 10 Americans currently lacks adequate access to health care. To increase access, we work closely with governments and community organizations. In the U.S., our community programs reached nearly 11 million people over the past year, improving access to health care, providing nutritious food and strengthening education in science and math.
People
Supporting performance and innovation
Takeda employs approximately 50,000 people around the world. We’re always looking to the future, developing the skills and talent we’ll need in the years ahead.
We encourage a culture of lifelong learning, and create a diverse and inclusive work environment.
As Takeda, our role is to support and enable employees. To do this, we offer extensive online and in-person training, mentoring programs and a Career Navigator, which allows employees to explore new career opportunities within the company.
At the same time, we believe leaders have a critical role to play in inspiring and motivating employees. That’s why we’ve made leadership development a priority. Over the past year, we’ve launched a Change Management toolkit – and introduced development programs to help prepare new leaders for future strategic roles.
The Top Employers’ Institute named Takeda as a top global employer for the eighth consecutive year. We’re just one of 17 companies to receive this recognition.
Employees by country and region (end-FY2024)
AI is transforming our HR approach
With AI, we’re able to provide more personalized advice and resources to our employees. We’re experimenting with AI coaches and role-playing, so employees can practice new skills in a risk-free environment. In July 2024, we launched Everyday AI – the first major step in our new Digital Dexterity framework, aimed at strengthening essential digital skills across the organization.
Planet
Healthier planet = healthier people
Our health depends on that of our planet. That’s why we’re working to minimize the environmental impact of our operations. We’re doing so by reducing our greenhouse gas (GHG) emissions, cutting back both waste to landfill and freshwater withdrawals, and using more sustainable packaging.
Since FY2016, we have reduced GHG emissions from our operations by 55%, well ahead of our original target. We have achieved this by increasing energy efficiency, switching to cleaner renewables and installing photovoltaic panels at our manufacturing sites.
We realize, however, that approximately 90% of our emissions come from outside our own operations – either from the goods and services we use to make our medicines, or from the disposal of our products and packaging after use. So, we’re working closely with our suppliers to help reduce upstream emissions and building sustainability into the design of our products.
Net-zero targets
In FY2024, our net-zero targets were validated by the Science Based Targets initiative (SBTi). To support our targets, we’ve established comprehensive net zero roadmaps for each manufacturing site to reduce emissions across the business. By FY2040, our aim is to have reduced combined Scope 1, 2 and 3 emissions by 90% against their respective base years, with Scope 1 and 2 achieving that reduction level by FY2035. For the remaining 10%, we’re currently building our strategy to invest in high-quality carbon removal projects through the Voluntary Carbon Market (VCM).
Sign up for our investors newsletter
Stay up to date on financial results, corporate milestones and learn how we're delivering on our commitment to patients, our people and the planet.
Sign up